Kainova Therapeutics

Illkirch, France

Kainova Therapeutics develops small molecules targeting G-coupled protein receptors.

$23.5M raised

Feb 2026

Series B

Biotechnology Health Care Pharmaceutical Therapeutics

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Kainova Therapeutics

How much funding has Kainova Therapeutics raised?

Kainova Therapeutics has raised $23.5M in total funding. The most recent round was Series B. The last funding was announced in February 2026.

Where is Kainova Therapeutics headquartered?

Kainova Therapeutics is headquartered in Illkirch, France.

What does Kainova Therapeutics do?

Kainova Therapeutics develops small molecules targeting G-coupled protein receptors.

What stage is Kainova Therapeutics at?

Kainova Therapeutics is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated February 9, 2026.

MLA

"Kainova Therapeutics — Funding & Investors." VCBacked, February 9, 2026, https://www.vcbacked.co/company/kainova-therapeutics. Accessed June 3, 2026.

APA

VCBacked. (2026). Kainova Therapeutics — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/kainova-therapeutics

Wikipedia (cite web)

{{cite web |title=Kainova Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/kainova-therapeutics |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated February 9, 2026.